Galmed Shares Up 200% After Co.'s 6 mg Aramchol NASH Candidate Earlier Received Regulatory Approvable Endpoint; Aramchol Showed NASH Resolution Without Worsening Of Fibrosis In Patients
Benzinga Newsdesk